191 related articles for article (PubMed ID: 9038378)
1. Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2.
Besser D; Bardelli A; Didichenko S; Thelen M; Comoglio PM; Ponzetto C; Nagamine Y
Oncogene; 1997 Feb; 14(6):705-11. PubMed ID: 9038378
[TBL] [Abstract][Full Text] [Related]
2. Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus.
Fixman ED; Naujokas MA; Rodrigues GA; Moran MF; Park M
Oncogene; 1995 Jan; 10(2):237-49. PubMed ID: 7838524
[TBL] [Abstract][Full Text] [Related]
3. Elucidation of a signaling pathway induced by FGF-2 leading to uPA gene expression in NIH 3T3 fibroblasts.
Besser D; Presta M; Nagamine Y
Cell Growth Differ; 1995 Aug; 6(8):1009-17. PubMed ID: 8547215
[TBL] [Abstract][Full Text] [Related]
4. MUC20 suppresses the hepatocyte growth factor-induced Grb2-Ras pathway by binding to a multifunctional docking site of met.
Higuchi T; Orita T; Katsuya K; Yamasaki Y; Akiyama K; Li H; Yamamoto T; Saito Y; Nakamura M
Mol Cell Biol; 2004 Sep; 24(17):7456-68. PubMed ID: 15314156
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator gene regulation by polyomavirus middle-T antigen.
Besser D; Urich M; Sakaue M; Messerschmitt A; Ballmer-Hofer K; Nagamine Y
Oncogene; 1995 Dec; 11(11):2383-91. PubMed ID: 8570190
[TBL] [Abstract][Full Text] [Related]
6. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway.
Paumelle R; Tulasne D; Kherrouche Z; Plaza S; Leroy C; Reveneau S; Vandenbunder B; Fafeur V
Oncogene; 2002 Apr; 21(15):2309-19. PubMed ID: 11948414
[TBL] [Abstract][Full Text] [Related]
8. Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis.
Bardelli A; Basile ML; Audero E; Giordano S; Wennström S; Ménard S; Comoglio PM; Ponzetto C
Oncogene; 1999 Feb; 18(5):1139-46. PubMed ID: 10022119
[TBL] [Abstract][Full Text] [Related]
9. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
10. Differential requirement of Grb2 and PI3-kinase in HGF/SF-induced cell motility and tubulogenesis.
Royal I; Fournier TM; Park M
J Cell Physiol; 1997 Nov; 173(2):196-201. PubMed ID: 9365521
[TBL] [Abstract][Full Text] [Related]
11. Involvement of the actin network in insulin signalling.
Tsakiridis T; Wang Q; Taha C; Grinstein S; Downey G; Klip A
Soc Gen Physiol Ser; 1997; 52():257-71. PubMed ID: 9210235
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1.
Recio JA; Merlino G
Cancer Res; 2003 Apr; 63(7):1576-82. PubMed ID: 12670907
[TBL] [Abstract][Full Text] [Related]
13. Cytoskeletal reorganization leads to induction of the urokinase-type plasminogen activator gene by activating FAK and Src and subsequently the Ras/Erk signaling pathway.
Irigoyen JP; Nagamine Y
Biochem Biophys Res Commun; 1999 Sep; 262(3):666-70. PubMed ID: 10471383
[TBL] [Abstract][Full Text] [Related]
14. Association of Grb2 with Sos and Ras with Raf-1 upon gamma irradiation of breast cancer cells.
Suy S; Anderson WB; Dent P; Chang E; Kasid U
Oncogene; 1997 Jul; 15(1):53-61. PubMed ID: 9233777
[TBL] [Abstract][Full Text] [Related]
15. Activation of the JNK pathway is essential for transformation by the Met oncogene.
Rodrigues GA; Park M; Schlessinger J
EMBO J; 1997 May; 16(10):2634-45. PubMed ID: 9184210
[TBL] [Abstract][Full Text] [Related]
16. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
Rodrigues GA; Park M
Oncogene; 1994 Jul; 9(7):2019-27. PubMed ID: 8208547
[TBL] [Abstract][Full Text] [Related]
17. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
Comoglio PM
EXS; 1993; 65():131-65. PubMed ID: 8380735
[TBL] [Abstract][Full Text] [Related]
18. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
Ried S; Jäger C; Jeffers M; Vande Woude GF; Graeff H; Schmitt M; Lengyel E
J Biol Chem; 1999 Jun; 274(23):16377-86. PubMed ID: 10347197
[TBL] [Abstract][Full Text] [Related]
19. Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene.
Lengye E; Singh B; Gum R; Nerlov C; Sabichi A; Birrer M; Boyd D
Oncogene; 1995 Dec; 11(12):2639-48. PubMed ID: 8545121
[TBL] [Abstract][Full Text] [Related]
20. Platelet-activating factor enhances urokinase-type plasminogen activator gene expression in corneal epithelium.
Tao Y; Bazan HE; Bazan NG
Invest Ophthalmol Vis Sci; 1996 Sep; 37(10):2037-46. PubMed ID: 8814143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
